198 related articles for article (PubMed ID: 33647028)
21. The role of latency reversal agents in the cure of HIV: A review of current data.
Bashiri K; Rezaei N; Nasi M; Cossarizza A
Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
[TBL] [Abstract][Full Text] [Related]
22. HIV Exploits Antiviral Host Innate GCN2-ATF4 Signaling for Establishing Viral Replication Early in Infection.
Jiang G; Santos Rocha C; Hirao LA; Mendes EA; Tang Y; Thompson GR; Wong JK; Dandekar S
mBio; 2017 May; 8(3):. PubMed ID: 28465428
[TBL] [Abstract][Full Text] [Related]
23. Nonhuman Primate Testing of the Impact of Different Regulatory T Cell Depletion Strategies on Reactivation and Clearance of Latent Simian Immunodeficiency Virus.
Sivanandham R; Kleinman AJ; Sette P; Brocca-Cofano E; Kilapandal Venkatraman SM; Policicchio BB; He T; Xu C; Swarthout J; Wang Z; Pandrea I; Apetrei C
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669326
[TBL] [Abstract][Full Text] [Related]
24. Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors.
Painter MM; Zaikos TD; Collins KL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021396
[TBL] [Abstract][Full Text] [Related]
25. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
26. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
J Virol; 2018 May; 92(10):. PubMed ID: 29343578
[TBL] [Abstract][Full Text] [Related]
27. Antibody-Mediated CD4 Depletion Induces Homeostatic CD4
Kumar NA; McBrien JB; Carnathan DG; Mavigner M; Mattingly C; White ER; Viviano F; Bosinger SE; Chahroudi A; Silvestri G; Paiardini M; Vanderford TH
J Virol; 2018 Nov; 92(22):. PubMed ID: 30185596
[TBL] [Abstract][Full Text] [Related]
28. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
[TBL] [Abstract][Full Text] [Related]
29. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
[TBL] [Abstract][Full Text] [Related]
30. Impact of non-thermal plasma treatment on MAPK signaling pathways of human immune cell lines.
Bundscherer L; Wende K; Ottmüller K; Barton A; Schmidt A; Bekeschus S; Hasse S; Weltmann KD; Masur K; Lindequist U
Immunobiology; 2013 Oct; 218(10):1248-55. PubMed ID: 23735483
[TBL] [Abstract][Full Text] [Related]
31. Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.
Sung JA; Sholtis K; Kirchherr J; Kuruc JD; Gay CL; Nordstrom JL; Bollard CM; Archin NM; Margolis DM
EBioMedicine; 2017 Sep; 23():52-58. PubMed ID: 28803740
[TBL] [Abstract][Full Text] [Related]
32. Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
Kristoff J; Palma ML; Garcia-Bates TM; Shen C; Sluis-Cremer N; Gupta P; Rinaldo CR; Mailliard RB
EBioMedicine; 2019 May; 43():295-306. PubMed ID: 30952614
[TBL] [Abstract][Full Text] [Related]
33. Short communication: HIV antigen-specific reactivation of HIV infection from cellular reservoirs: implications in the settings of therapeutic vaccinations.
Shete A; Thakar M; Singh DP; Gangakhedkar R; Gaikwad A; Pawar J; Paranjape R
AIDS Res Hum Retroviruses; 2012 Aug; 28(8):835-43. PubMed ID: 21936714
[TBL] [Abstract][Full Text] [Related]
34. The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques.
Webb GM; Molden J; Busman-Sahay K; Abdulhaqq S; Wu HL; Weber WC; Bateman KB; Reed JS; Northrup M; Maier N; Tanaka S; Gao L; Davey B; Carpenter BL; Axthelm MK; Stanton JJ; Smedley J; Greene JM; Safrit JT; Estes JD; Skinner PJ; Sacha JB
PLoS Pathog; 2020 Mar; 16(3):e1008339. PubMed ID: 32163523
[TBL] [Abstract][Full Text] [Related]
35. CXCR4-Using HIV Strains Predominate in Naive and Central Memory CD4
Roche M; Tumpach C; Symons J; Gartner M; Anderson JL; Khoury G; Cashin K; Cameron PU; Churchill MJ; Deeks SG; Gorry PR; Lewin SR
J Virol; 2020 Feb; 94(6):. PubMed ID: 31852784
[TBL] [Abstract][Full Text] [Related]
36. BCL6 Inhibitor-Mediated Downregulation of Phosphorylated SAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation.
Cai Y; Abdel-Mohsen M; Tomescu C; Xue F; Wu G; Howell BJ; Ai Y; Sun J; Azzoni L; Le Coz C; Romberg N; Montaner LJ
J Virol; 2019 Jan; 93(2):. PubMed ID: 30355686
[TBL] [Abstract][Full Text] [Related]
37. An M2 Rather than a T
Lee DH; Ghiasi H
J Virol; 2018 May; 92(10):. PubMed ID: 29491152
[TBL] [Abstract][Full Text] [Related]
38. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.
López-Huertas MR; Gutiérrez C; Madrid-Elena N; Hernández-Novoa B; Olalla-Sierra J; Plana M; Delgado R; Rubio R; Muñoz-Fernández MÁ; Moreno S
Sci Rep; 2020 Dec; 10(1):22286. PubMed ID: 33339855
[TBL] [Abstract][Full Text] [Related]
39. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
40. A broad drug arsenal to attack a strenuous latent HIV reservoir.
Stoszko M; Ne E; Abner E; Mahmoudi T
Curr Opin Virol; 2019 Oct; 38():37-53. PubMed ID: 31323521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]